Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PiSARRO-R APR-246 + pegylated liposomal doxorubicin in platinum-resistant high-grade serous ovarian cancer
2017-000265-67Phase 2Completed
- Sponsor
- Aprea Therapeutics
- Start
- Mar 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eprenetapopt and doxorubicin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Aprea Therapeutics. Primary endpoint: Overall response rate. Started Mar 2017; status: completed.
02
Drugs
eprenetapoptdoxorubicin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2017-000265-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000265-67.